Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Qure.ai and Project Data Sphere® Collaborate to Revolutionize Cancer Care with AI-Enabled Tumor Assessments in Clinical Trials

NextEdge Admin

14 Dec 2023

3 min 24 sec

Qure.ai, a leader in AI solutions for medical imaging, has partnered with Project Data Sphere®, a nonprofit initiative of the CEO Roundtable on Cancer, to advance cancer care through AI-enabled solutions in tumor assessments for clinical trials. The collaboration aims to enhance efficiency and consistency in evaluating cancer treatment effectiveness, ultimately elevating the quality of patient care.

The focal point of the collaboration is autoRECIST, a product from Project Data Sphere’s Images and Algorithms program, developed in consultation with the U.S. Food and Drug Administration. With input from stakeholders across the pharmaceutical industry and academia, autoRECIST addresses the crucial need for automating and standardizing tumor response assessments in medical imaging. This AI clinical tool, rooted in current imaging guidelines, assists radiologists in detecting, selecting, measuring, and tracking lesions using defined criteria.

autoRECIST is poised to improve clinical trials and cancer treatments by enhancing efficiency and accuracy through the automation of analyzing medical images, such as CT scans, and reducing variability in measuring tumor size over time. Additionally, it facilitates faster decision-making in assessing tumor response, allowing researchers and clinicians to swiftly determine treatment effectiveness or the need for changes in care.

The collaboration enables the exchange of unique insights, advanced methodologies, and access to a broader network of industry leaders, enriching the development of the autoRECIST solution. According to Jon McDunn, President of Project Data Sphere, the program holds the promise of improving processes and expediting the delivery of lifesaving treatments to patients.

Prashant Warier, CEO and Co-founder of Qure.ai, emphasized the groundbreaking nature of this collaboration in harnessing the transformative power of AI in cancer treatment. The development of autoRECIST reflects Qure.ai’s unwavering commitment to combating cancer, with a resolute focus on early detection to significantly advance clinical trial methodologies and change the landscape of cancer care.

This collaboration signifies a joint effort by Qure.ai and Project Data Sphere to make substantial advancements in cancer care, leveraging AI technology to potentially reshape the landscape of cancer clinical trials and generate more effective and precise treatments for those affected by cancer.